Clinical trial
A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
NCT00782275 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2009
- Completion date
- May 31, 2015
- Enrollment
- 41 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
kidney cancer, renal cell carcinoma